3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
5
Neoplasms
4
Lung Neoplasms
4
Prostatic Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Advanced Solid Tumors
3
Urinary Bladder Neoplasms
2
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Part A and B: Advanced Solid Malignancies
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Interventions
Carboplatin
30
Cisplatin
23
pembrolizumab
22
Paclitaxel
21
Pemetrexed
20
Gemcitabine
10
osimertinib
9
durvalumab
9
Nivolumab
9
130-nm albumin-bound paclitaxel
8
Sunitinib
7
Sorafenib
7
Fluorouracil
7
Everolimus
7
Docetaxel
7
Axitinib
7
Cetuximab
6
epothilone B
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
volociximab
4
trebananib
4
reolysin
4
catumaxomab
4
cabozantinib
4
atezolizumab
4
Radiotherapy
4
Ipilimumab
4
vosaroxin
3
liposomal doxorubicin
3
lenvatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma
×
tremelimumab
×
Clear all
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA